Summary & Overview
CPT 64612: Unilateral Facial Nerve Chemical Neurolysis
CPT code 64612 represents unilateral chemical neurolysis of the facial nerve performed to relieve painful facial nerve disorders or to reduce abnormal involuntary facial movements. As a targeted interventional procedure, it matters nationally because it is used when medical therapies are insufficient and can affect utilization of outpatient surgical services, procedural coding accuracy, and payer coverage determinations for facial pain and movement disorders.
Key payers commonly considered in coverage and reimbursement discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical and coding overview, typical sites of service and service type, and a summary of the payer landscape and common billing considerations. The content addresses how the procedure is categorized in procedural coding, typical clinical indications, and where to expect the service to be delivered.
This publication aims to provide clinicians, billers, and policy analysts with clear context for CPT code 64612, including benchmarks related to service delivery and payer coverage norms where available, plus any relevant policy updates or coding guidance impacting national reimbursement and utilization trends.
Billing Code Overview
CPT code 64612 describes a procedure in which a provider injects a chemical agent on one side of the face to interrupt the facial nerve, with the clinical intent of relieving painful facial nerve disorders or reducing abnormal involuntary movements of facial muscles. This procedure is a targeted facial nerve chemical neurolysis or chemodenervation performed unilaterally.
-
Service type: Minor surgical/interventional nerve lesioning procedure (chemical neurolysis/chemodenervation)
-
Typical site of service: Outpatient surgical setting, ambulatory surgery center, or physician office with procedural capability
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient presents to an outpatient neurology clinic with right-sided hemifacial spasm causing frequent, involuntary contractions of the facial muscles that impair eating and social function. Evaluation includes history, physical exam, and prior trials of oral medications (e.g., antispasmodics) that provided inadequate relief or caused intolerable side effects. After obtaining informed consent, the patient is scheduled for a percutaneous, targeted chemical neurolysis of the right facial nerve in a procedure suite or ambulatory surgical center. Under monitored anesthesia care or local anesthesia with sedation, the physician identifies the targeted branch(es) of the facial nerve using anatomical landmarks and, if indicated, electromyographic mapping. A controlled injection of a neurolytic agent is administered to the affected side to disrupt aberrant facial nerve transmission and relieve spasm. The patient is observed in recovery for potential complications (facial weakness, dysphagia, infection, hematoma) and given post-procedure instructions with follow-up to assess symptom relief and need for repeat treatments or alternative interventions such as botulinum toxin injections or microvascular decompression.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
50 | Bilateral procedure | Use when the injection is performed on both sides of the face during the same operative session. |